ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Seen Shifting Away From Comprehensive Center Emphasis Toward Encouraging Clinical Excellence

April 30, 1976

NCAB Meeting Moved To October

July 20, 1979

ASCO Urges Sustained Support For Cancer Research, Clinical Trials

March 27, 2009

14th Cancer Congress Big Success; CICA Satellite Established; US, USSR Renew Cancer Agreement

September 12, 1986

Construction Needs From NCI Said $40 Million Year For Four Years

June 9, 1978

Carcinogenicity Test For Cis-Platinum Needed, DCT Says, But Declines To Pay For It

June 16, 1978